Pasar al contenido principal

SUPERANDO LOS RETOS ACTUALES DE LA INMUNOTERAPIA CAR-T FRENTE A LA LEUCEMIA LLA-T: OPTIMIZACION DE CARS (TRUCS) Y GENERACION DE CELULAS T EFECTORAS ALOGENICAS UNIVERSALES

PID2022-138880OB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2022
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Glutathione overproduction mediates lymphoma initiating cells survival and has a sex-dependent effect on lymphomagenesis

  • Hernández Alcántara, Alberto
  • Kourani, Omar
  • Marcos-Jiménez, Ana
  • Martínez-Núñez, Patricia
  • Herranz-Martín, E.
  • Fuentes, Patricia
  • Toribio, María L.
  • Muñoz-Calleja, Cecilia
  • Iglesias, Teresa
  • Campanero, Miguel R.
Lymphoid tumor patients often exhibit resistance to standard therapies or experience relapse post-remission. Relapse is driven by Tumor Initiating Cells (TICs), a subset of tumor cells capable of regrowing the tumor and highly resistant to therapy. Growing cells in 3D gels is a method to discern tumorigenic cells because it strongly correlates with tumorigenicity. The finding that TICs, rather than differentiated tumor cells, grow in 3D gels offers a unique opportunity to unveil TIC-specific signaling pathways and therapeutic targets common to various cancer types. Here, we show that culturing lymphoid cells in 3D gels triggers reactive oxygen species (ROS) production, leading to non-tumor lymphoid cell death while enabling the survival and proliferation of a subset of lymphoma/leukemia cells, TICs or TIC-like cells. Treatment with the antioxidant N-acetylcysteine inhibits this lethality and promotes the growth of primary non-tumor lymphoid cells in 3D gels. A subset of lymphoma cells, characterized by an increased abundance of the antioxidant glutathione, escape ROS-induced lethality, a response not seen in non-tumor cells. Reducing glutathione production in lymphoma cells, either through pharmacological inhibition of glutamate cysteine ligase (GCL), the enzyme catalyzing the rate-limiting step in glutathione biosynthesis, or via knockdown of GCLC, the GCL catalytic subunit, sharply decreased cell growth in 3D gels and xenografts. Tumor cells from B-cell lymphoma/leukemia patients and λ-MYC mice, a B-cell lymphoma mouse model, overproduce glutathione. Importantly, pharmacological GCL inhibition hindered lymphoma growth in female λ-MYC mice, suggesting that this treatment holds promise as a therapeutic strategy for female lymphoma/leukemia patients., The CBM is supported by Consejo Superior de Investigaciones Científicas and Universidad Autónoma de Madrid, and is a Severo Ochoa Center of Excellence (grant CEX2021-001154-S) funded by MICIN/AEI/10.13039/501100011033. This work was supported by Fundación de la Asociación Española contra el Cáncer (AECC) grant PROYE20060CAMP to M.R.C., grant PID2022-138880OB-I00 funded by MCIN /AEI /10.13039/501100011033 / FEDER, UE to M.L.T., grant PID2020-115218RB-I00 funded by MCIN/AEI/10.13039/501100011033 to T.I., and Instituto de Salud Carlos III (CIBERNED) to T.I. O.K. held an FPI fellowship from the Spanish Ministerio de Educacion y Ciencia (BES-2014-069236)., With funding from the Spanish government through the ‘Severo Ochoa Centre of Excellence’ accreditation (CEX2021-001154-S)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

CAR-T cells targeting CCR9 and CD1a for the treatment of T cell acute lymphoblastic leukemia

  • Tirado, Néstor
  • Fidyt, Klaudyna
  • Mansilla, María José
  • Garcia-Perez, Alba
  • Martínez-Moreno, Alba
  • Vinyoles, Meritxell
  • Alcain, Juan
  • García-Peydró, Marina
  • Roca-Ho, Heleia
  • Fernandez-Fuentes, Narcis
  • Guerrero-Murillo, Mercedes
  • Falgàs, Aïda
  • Velasco-Hernandez, Talia
  • Bueno, Clara
  • Panelli, Patrizio
  • Mulens-Arias, Vladimir
  • Apostolov, Apostol
  • Engel, Pablo
  • González, Europa Azucena
  • Vick, Binje
  • Jeremias, Irmela
  • Caye-Eude, Aurélie
  • Baruchel, André
  • Cavé, Hélène
  • Genescà, Eulàlia
  • Ribera, Jordi
  • Díaz-Beyá, Marina
  • Martínez-Sánchez, María Victoria
  • Fuster, José Luis
  • Escudero López, Adela
  • Minguillón, Jordi
  • Pérez-Martínez, Antonio
  • Ramírez-Orellana, Manuel
  • Torrebadell, Montserrat
  • Díaz, Víctor M.
  • Toribio, María L.
  • Sánchez-Martínez, Diego
  • Menéndez, Pablo
T cell acute lymphoblastic leukemia (T-ALL) is an aggressive malignancy characterized by high rates of induction failure and relapse, and effective targeted immunotherapies are lacking. Despite promising clinical progress with genome-edited CD7-directed CAR-T cells, which present significant logistical and regulatory issues, CAR-T cell therapy in T-ALL remains challenging due to the shared antigen expression between malignant and healthy T cells. This can result in CAR-T cell fratricide, T cell aplasia, and the potential for blast contamination during CAR-T cell manufacturing. Recently described CAR-T cells target non-pan-T antigens, absent on healthy T cells but expressed on specific T-ALL subsets. These antigens include CD1a (NCT05679895), which is expressed in cortical T-ALL, and CCR9. We show that CCR9 is expressed on >70% of T-ALL patients (132/180) and is maintained at relapse, with a safe expression profile in healthy hematopoietic and non-hematopoietic tissues. Further analyses showed that dual targeting of CCR9 and CD1a could benefit T-ALL patients with a greater blast coverage than single CAR-T cell treatments. We therefore developed, characterized, and preclinically validated a novel humanized CCR9-specific CAR with robust and specific antileukemic activity as a monotherapy in vitro and in vivo against cell lines, primary T-ALL samples, and patient-derived xenografts. Importantly, CCR9/CD1a dual-targeting CAR-T cells showed higher efficacy than single-targeting CAR-T cells, particularly in T-ALL cases with phenotypically heterogeneous leukemic populations. Dual CD1a/CCR9 CAR-T therapy may prevent T cell aplasia and obviate the need for allogeneic transplantation and regulatory-challenging genome engineering approaches in T-ALL., Research in PM laboratory is supported by CERCA/Generalitat de Catalunya and Fundació Josep Carreras-Obra Social la Caixa for core support, the European Research Council grants (ERC-PoC-957466 IT4B-TALL, ERC-PoC-101100665 BiTE-CAR); H2020 (101057250-CANCERNA), the Spanish Research Agency (AEI) (PID2022-142966OB-I00 funded by MCIN/AEI/10.13039/501100011033 https://doi.org/10.13039/501100011033 and FEDER Funds, and CPP2021-008508, CPP2021-008676, CPP2022-009759 funded by MICIU/AEI/10.13039/501100011033 and the European Union NextGenerationEU/PRTR); “Ayudas Merck de Investigación” from Health Merck Foundation, and grant PID2022-136554OA-I00 funded by MICIU/AEI/10.13039/501100011033 https://doi.org/10.13039/501100011033 and the European Regional Development Fund (ERDF)/EU to DS-M; the AEI grant PID2022-138880OB-I00 to MLT, the Spanish Association Against Cancer (AECC, PRYGN234975MENE, PRYGN211192BUEN), the Uno Entre Cien Mil Foundation to MLT and to CB, and the Instituto de Salud Carlos III (ISCIII) through the Spanish Network of Advanced Therapies (RICORS/TERAV+), projects RD24/0014/0015, RD24/0014/0024 and RD24/0014/0042 and co-funded by the European Union (EU). AF was supported by a Juan de la Cierva postdoctoral fellowship (FJC2021-046789-I), VMD by a Torres Quevedo contract (PTQ2020-011056), AG-P by an industrial PhD fellowship (DIN2022-012556) and NT by a PhD fellowship (FPU19/00039) from the Spanish Ministry of Science and Innovation. KF is supported by the European Union’s Marie Skłodowska-Curie Actions (MSCA) Postdoctoral Fellowship (101153028). MVM-S is supported by the Asociación Pablo Ugarte (APU).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Combined dendritic cell and anti-TIGIT immunotherapy potentiates adaptive NK cells against HIV-1

  • Sánchez-Cerrillo, Ildefonso
  • Agudo-Lera, María
  • Popova, Olga
  • Tsukalov, Ilya
  • Calvet-Mirabent, Marta
  • de los Santos, Ignacio
  • García-Fraile, Lucio
  • Fuentes, Patricia
  • Delgado-Arévalo, Cristina
  • Alcain, Juan
  • Sánchez-Gaona, Nerea
  • Grau-Expósito, Judith
  • Lázaro-Díez, María
  • Muñoz-Calleja, Cecilia
  • Alfranca, Arantzazu
  • Genescà, Meritxell
  • Prado, Julia G.
  • Vrbanac, Vladimir
  • Balazs, Alejandro
  • Buzón, María José
  • Toribio, María L.
  • Muñoz-Fernández, María A.
  • Sánchez-Madrid, Francisco
  • Martín-Gayo, Enrique
Natural Killer (NK) cells are promising candidates for targeting persistently infected CD4 + T cells in people with HIV-1 (PWH). However, chronicity of HIV-1 infection impairs NK cell functionality, requiring additional strategies to potentiate their cytotoxic activity. This study demonstrates that dendritic cells primed with nanoparticles containing Poly I:C (Nano-PIC-MDDC) enhance the natural cytotoxic function of NK cells from effective responder PWH. These NK cells exhibit increased proportions of NKG2C+ cell subsets capable of eliminating HIV-1 infected CD4 + T cells through the TRAIL receptor. In contrast, in non-responder PWH, elevated expression of the inhibitory receptor TIGIT is associated with reduced frequencies of NKG2C + NK cells and diminished TRAIL expression. TIGIT blockade restores cytotoxicity of NK cells from non-responder PWH against HIV-1-infected cells by upregulating TRAIL. Furthermore, combining Nano-PIC-MDDC-primed NK cells with anti-TIGIT immunotherapy in humanized NSG mice reduces the expansion of HIV-1 infected cells, preserves NKG2C + NK cell precursors and increases TRAIL expression in tissue. Collectively, these findings support the combined use of Nano-PIC-MDDC and TIGIT blockade as a promising immunotherapeutic strategy toward an HIV-1 cure., EMG was supported by Ramón y Cajal Program (RYC2018-024374-I), the Spanish Agencia Estatal de Investigación RETOS, Generación de conocimiento and consolidation programs (RTI2018-097485-A-I00; PID2021-127899OB-I00; CNS2023-144841), La Caixa Banking Foundation ETI-CureHIV (HR20-00218), GLD24/00117 grant from Gilead Biosciences and infectious diseases CIBER (CIBERINFEC) from ISCIII (CB21/13/00107). MAL was supported by the Formación de Personal Investigador (FPI) grant PRE2022-104516. IT was supported by FPI UAM fellowship. CDA was supported by Comunidad de Madrid Talento Program (2017-T1/BMD-5396). MCM was supported by La Caixa Foundation ETI-CureHIV (HR20-00218). P2022/BMD7209-INTEGRAMUNE from Comunidad Autónoma de Madrid and La Caixa Health Research Grant LCF/PR/HR23/52430018 to and PID2023-149541OB-I00 FSM also supported the study. ISC was supported by infectious diseases CIBER from ISCIII (CB21/13/00107). JGP was supported by La Caixa Health program ETI-CureHIV project (HR20-00218), the CIBERINFECC from the National Health Institute Carlos III, and the project PI22/01120. MLT was supported by the Spanish Agencia Estatal de Investigación, Ministerio de Ciencia, Innovación y Universidades (PID2022-138880OB-I00 and PDC2021-121238-I00). NMC contributed to ROC Curve analysis.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Pre-TCR-targeted immunotherapy for T cell acute lymphoblastic leukemia

  • Fuentes, Patricia
  • García-Peydró, Marina
  • Alcain, Juan
  • Mosquera, Marta
  • Cela, Carmela
  • Cifuentes, Claudia
  • Torrebadell, Montserrat
  • Isola, Ignacio
  • Camós, Mireia
  • Ramírez, Manuel
  • Alarcón, Balbino
  • Toribio, María L.
Targeted immunotherapy for T cell acute lymphoblastic leukemia (T-ALL), an aggressive tumor of developing T cell progenitors, is an urgent unmet need, especially for relapsed/refractory disease. Selective T-ALL targeting is challenging due to the shared antigen expression between leukemic and normal T cells. Here we identify the pre-T cell receptor (pre-TCR), a surface receptor essential for T cell development, as a biomarker of leukemia-initiating cells (LICs) in human T-ALL. Loss-of-function genetic approaches demonstrate that pre-TCR signaling is necessary for LIC activity and tumor progression in pre-TCR T-ALL patient xenografts in mice. Furthermore, we demonstrate the specific therapeutic targeting of the pre-TCR with a monoclonal antibody against the invariant pTα subunit of the human pre-TCR, and validate an anti-pTα antibody–drug conjugate in vivo treatment as a potent immunotherapy for inhibiting LIC activity and tumor progression of T-ALL in mice. These findings reveal the suitability of pre-TCR targeting as a promising therapy for the treatment of individuals with relapsed/refractory T-ALL expressing the pre-TCR., This research was supported in part by grants PID2019-105623RB-I00, PID2022-138880OB-I00 and PDC2021-121238-I00 funded by Ministerio de Ciencia, Innovación y Universidades. Agencia Estatal de Investigación (MCIN/AEI/ 10.13039/501100011033/European Regional Development Fund, European Union), and by grants from Fundación Unoentrecienmil and Fundación Inocente Inocente to M.L.T. Institutional grants from the Fundación Ramón Areces and Banco de Santander to the Centro de Biología Molecular Severo Ochoa are also acknowledged